Treatment News : Quad Pill Measures Up to Two Other HIV Drug Regimens

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 22, 2013

Quad Pill Measures Up to Two Other HIV Drug Regimens

Ninety-six week data from two randomized clinical trials show that the single-pill, once-daily antiretroviral therapy Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir), also known as the “Quad” pill, is as effective as both Atripla (efavirenz, emtricitabine, tenofovir) and a Reyataz plus Truvada combination (atazanavir plus emtricitabine/tenofovir), MedPage Today reports. Researchers recruited 1,408 HIV-positive study participants and randomly assigned 701 to receive Stribild, 352 to take Atripla and 355 to take Reyataz plus Truvada. They presented their findings at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

After 96 weeks of treatment, 84 percent of the participants taking Stribild achieved an undetectable viral load, compared with 82 percent experiencing full viral suppression in both of the other two therapy groups. These results were consistent regardless of age, sex, race and the participants’ viral load and CD4 levels at the beginning of the study.

Stribild bested the other drug regimens in the side effects category, particularly when it came to Atripla’s neuropsychiatric effects. Fourteen percent of those taking Atripla reported abnormal dreams, compared with 5 percent of those taking Reyataz and Truvada and just 1 percent of those taking Stribild. Four percent of those in the Atripla arm reported dizziness, compared with 1 percent of those in the other study arms.

The improvement in CD4 count when compared with the study’s baseline was similar among the three arms, with those taking Stribild gaining an average of 275 CD4s, those taking Atripla gaining 273 cells and those in the Reyataz plus Truvada arm seeing an increase of 261 CD4s.

To read the MedPage Today story, click here.

To read the conference abstract, click here.

Search: Quad, Atripla, Stribild, elvitegravir, cobicistat, emtricitabine, tenofovir, efavirenz, atazanavir, MedPage Today, Reyataz, Truvada, 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, IAS 2013, side effects, efficacy.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    aqua_31206
    Macon
    Georgia


    TanyaB
    Delray Beach
    Florida


    Heartland4now
    Tacoma
    Washington


    jap022964
    el dorado
    Arkansas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.